Results 51 to 60 of about 352,135 (348)

Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.

Blood, 2020
Over 90% of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) harbor somatic mutations in myeloid-related genes, but still, current diagnostic criteria do not include molecular data. We performed genome-wide sequencing techniques to characterize the
L. Palomo, M. Meggendorfer, S. Hutter, S. Twardziok, V. Adema, Irene Fuhrmann, F. Fuster-Tormo, B. Xicoy, L. Zamora, P. Acha, C. Kerr, W. Kern, J. Maciejewski, F. Solé, C. Haferlach, T. Haferlach   +15 more
semanticscholar   +1 more source

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Blood, 2022
Key Points • Mutant CALR proteins are secreted in complex with sTFR1 to the plasma of MPN patients and activate the TpoR in a rogue cytokine fashion.• TpoR-expressing cells with a CALR mutation are uniquely sensitive to the levels of circulating mutant ...
C. Pecquet, Nicolas Papadopoulos, Thomas Balligand, Ilyas Chachoua, A. Tisserand, G. Vertenoeil, A. Nédélec, D. Vertommen, A. Roy, C. Marty, Harini Nivarthi, J. Defour, Mira El-Khoury, E. Hug, A. Majoros, Erica Xu, O. Zagrijtschuk, T. E. Fertig, D. Marta, H. Gisslinger, B. Gisslinger, M. Schalling, I. Casetti, E. Rumi, D. Pietra, C. Cavalloni, L. Arcaini, M. Cazzola, Norio Komatsu, Yoshihiko Kihara, Yoshitaka Sunami, Y. Edahiro, Marito Araki, R. Lesyk, V. Buxhofer-Ausch, S. Heibl, Florence Pasquier, I. Plo, W. Vainchenker, R. Kralovics, S. Constantinescu   +40 more
semanticscholar   +1 more source

Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis [PDF]

, 2018
Background. The knowledge of natural history of patients with portal hypertension (PH) not due to cirrhosis is less well known than that of cirrhotic patients. Aim.
Aprile, Francesca, Gioia, Stefania, Merli, Manuela, Nardelli, Silvia, Nicoletti, Valeria, Pasquale, Chiara, Pentassuglio, Ilaria, Riggio, Oliviero   +7 more
core   +1 more source

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview

Frontiers in Oncology, 2021
The WHO-category Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) recognizes a unique group of clonal myeloid malignancies exhibiting overlapping features of myelodysplastic as well as myeloproliferative neoplasms.
Andrea Kuendgen, Annika Kasprzak, Ulrich Germing   +2 more
doaj   +1 more source

Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease [PDF]

, 2016
Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable ...
How, Joan, Oh, Stephen T, Zhou, Amy
core   +2 more sources

Update in the myeloproliferative neoplasms [PDF]

Clinical Medicine, 2014
The differential diagnosis of haematological abnormalities, such as leucocytosis, erythocytosis, thrombocytosis or indeed anaemia, is wide and disarming. Here we report on significant updates in the differential diagnosis of erythrocyosis and thrombocytosis presenting a simplified schema for the clinician.
Harrison, Claire N, McMullin, Mary F
openaire   +4 more sources

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms

Haematologica, 2011
Background Myeloproliferative neoplasms constitute a group of diverse chronic myeloid malignancies that share pathogenic features such as acquired mutations in the JAK2, TET2, CBL and MPL genes.
Damla Olcaydu, Elisa Rumi, Ashot Harutyunyan, Francesco Passamonti, Daniela Pietra, Cristiana Pascutto, Tiina Berg, Roland Jäger, Emma Hammond, Mario Cazzola, Robert Kralovics   +10 more
doaj   +1 more source

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives

Cells, 2021
Classical BCR-ABL-negative myeloproliferative neoplasms (MPN) are a heterogeneous group of hematologic malignancies, including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), as well as post-PV-MF and post-ET-MF ...
Julian Baumeister, Nicolas Chatain, Alexandros Marios Sofias, T. Lammers, S. Koschmieder   +4 more
semanticscholar   +1 more source

Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. [PDF]

, 2008
Systemic mastocytoses represent neoplastic proliferations of mast cells. In about 20% of cases systemic mastocytoses are accompanied by clonal haematopoietic non-mast cell-lineage disorders, most commonly myeloid neoplasms.
Dirnhofer, S., Horny, H.-P., Jotterand, M., Muhlematter, D., Sotlar, Karl, Theocharides, A., Tzankov, A., Went, P.   +7 more
core   +1 more source

Genetics of Myeloproliferative Neoplasms [PDF]

The Cancer Journal, 2014
In the last decade, genomic studies have identified multiple recurrent somatic mutations in myeloproliferative neoplasms (MPNs). Beginning with the discovery of the JAK2 V617F mutation, multiple additional mutations have been found that constitutively activate cell-signaling pathways, including MPL, CBL, and LNK.
Aaron D. Viny, Ross L. Levine
openaire   +3 more sources